[
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
    "summary": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3bf6df48412d23c69ca5d2ed38f976d348ff301770f70938e879ce76bc1cebbb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753979520,
      "headline": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
      "id": 136168341,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3bf6df48412d23c69ca5d2ed38f976d348ff301770f70938e879ce76bc1cebbb"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=956a6aa32f7a61c4503a25a64db3c76cab18e7c47d1232e8fe677f423667835d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753963822,
      "headline": "AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue",
      "id": 136151795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=956a6aa32f7a61c4503a25a64db3c76cab18e7c47d1232e8fe677f423667835d"
    }
  },
  {
    "ts": null,
    "headline": "Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT)",
    "summary": "Key Insights Abbott Laboratories' estimated fair value is US$133 based on 2 Stage Free Cash Flow to Equity With US$129...",
    "url": "https://finnhub.io/api/news?id=753697fb711d09ad88c39421b0d99e317e9d922298820af80df30e72acd95c06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753959615,
      "headline": "Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT)",
      "id": 136151848,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Abbott Laboratories' estimated fair value is US$133 based on 2 Stage Free Cash Flow to Equity With US$129...",
      "url": "https://finnhub.io/api/news?id=753697fb711d09ad88c39421b0d99e317e9d922298820af80df30e72acd95c06"
    }
  },
  {
    "ts": null,
    "headline": "UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a ‘Buy’ rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 […]",
    "url": "https://finnhub.io/api/news?id=469f43ae85c93e902f55495c4762fe4bbf0ea1e86fd81c5dcb92b7410a90b159",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753935835,
      "headline": "UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating",
      "id": 136148939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a ‘Buy’ rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 […]",
      "url": "https://finnhub.io/api/news?id=469f43ae85c93e902f55495c4762fe4bbf0ea1e86fd81c5dcb92b7410a90b159"
    }
  }
]